Horizon Discovery and AstraZeneca have entered into an exclusive collaboration and license agreement to explore Horizon's first-in-class kinase target programme, HD-001, as a means of developing novel therapies for multiple cancer types. HD-001 modulates a novel kinase, which is mutated in multiple cancer types including lung and colon tumours. What is more, the target seems to be crucial in cells with K-RAS mutations, which have been found in 40% of all cancers that have become resistant to available therapeutics.
The companies said that the preclinical programme have the potential for a blockbuster drugs as K-RAS defective cells are currently not druggable. Under the terms of the agreement, Horizon will receive undisclosed upfront and preclinical milestone payments, and are eligible for clinical and approval milestones totalling up to US$75m, as well as tiered royalties.
24.07.2015 Biotech companies across Europe continue to raise cash on the public markets, generating €3bn in total financing proceedings in the first half of 2015. Compared to 2014, this is almost twice as much.
23.07.2015 US money keeps flowing into Europe's biotechs. As the race for the peanut allergy market heats up, NASDAQ listed French biotech DBV has announced the successful closing of US$281m (€256m) share offering for its allergy products.
16.07.2015 Sanofi has announced plans to restructure its business in five standalone global business units starting in January 2016. The goal is to promote growth and help the company launch a catalogue of new drugs over the next five years.
15.07.2015 GlaxoSmithKline (GSK) has become the first drugmaker to join the Francis Crick Institute. It is a consortium made up of six scientific and academic institutes to conduct research and drug development in the UK. The new institute is set to become a world-leading centre of biomedical research and innovation.
10.07.2015 Karolinska Development has slashed the reported value of its portfolio by almost half by revising its valuation model for early stage companies and divesting its shares in pain med maker Pharmanest.
08.07.2015 Horizon Pharma plc. has set its sights on US-American speciality pharma company Depomed Inc. After getting nowhere with the rival’s board, Horizon has now launched a US$3bn hostile bid for the pain and CNS specialist.
07.07.2015 Irish pharma play Allergan plc. is boosting its eye care business by acquiring US-American medtech company Oculeve. Included in the deal are Oculeve’s dry eye disease development programmes.
The BioShake series contains high-speed mixer and thermal mixer for small and very small volumes in microplates and reaction tubes and allows for the first time high precise and efficient mixing in the microliter scale for a wide range of applications. more